Results 101 to 110 of about 128,389 (322)

Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms

OncoTarget, 2014
Resistance to Imatinib mesylate (IM) is an emerging problem for patients with chronic myelogenous leukemia (CML). T315I mutation in the Bcr-Abl is the predominant mechanism of the acquired resistance to IM and second generation tyrosine kinase inhibitors
Xin Chen, Xianping Shi, Chong Zhao, Xiaofen Li, Xiaoying Lan, Shouting Liu, Hongbiao Huang, Ningning Liu, Siyan Liao, D. Zang, Wenbin Song, Quentin Liu, B. Carter, Q. Dou, Xuejun Wang, Jinbao Liu   +15 more
semanticscholar   +1 more source

Role of STAT3 in transformation and drug resistance in CML

Frontiers in Oncology, 2012
Chronic Myeloid Leukemia (CML) is initially driven by the bcr-abl fusion oncoprotein. The identification of bcr-abl led to the discovery and rapid translation into the clinic of bcr-abl kinase inhibitors.
Rajesh R Nair, Joel H Tolentino, Lori A Hazlehurst   +2 more
doaj   +1 more source

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks [PDF]

, 2011
The resistance of leukemic stem cells in response to targeted therapies such as tyrosine kinase inhibitors (TKIs) relies on the cooperative activity of multiple signaling pathways and molecules, including TGFβ, AKT, and FOXO transcription factors ...
Austin, Bernardi, Bhatia, Brunet, Carayol, Chen, Chen, Druker, Duy, Fernández de Mattos, Francesca Pellicano, Graham, Hurtz, Ilaria, Ito, Komatsu, Lee, Mahon, Naka, Neubauer, Neviani, Neviani, Peng, Rowley, Samanta, Stambolic, Tessa L. Holyoake, Tothova, Xie, Yilmaz, Zhou   +30 more
core   +2 more sources

Transferred BCR/ABL DNA from K562 Extracellular Vesicles Causes Chronic Myeloid Leukemia in Immunodeficient Mice

PLoS ONE, 2014
Our previous study showed that besides mRNAs and microRNAs, there are DNA fragments within extracellular vesicles (EVs). The BCR/ABL hybrid gene, involved in the pathogenesis of chronic myeloid leukemia (CML), could be transferred from K562 EVs to ...
Jin Cai, Gengze Wu, Xiaorong Tan, Yu Han, Caiyu Chen, Chuanwei Li, Na Wang, X. Zou, Xinjian Chen, Faying Zhou, D. He, Lin Zhou, P. Jose, C. Zeng   +13 more
semanticscholar   +1 more source

Integration of Optical Genome Mapping in the Cytogenomic and Molecular Work‐Up of Hematological Malignancies: Expert Recommendations From the International Consortium for Optical Genome Mapping

American Journal of Hematology, Volume 100, Issue 6, Page 1029-1048, June 2025.
ABSTRACT The latest updates to the classification of hematolymphoid malignancies using the World Health Organization (WHO, 5th ed.) and ICC (International Consensus Classification) criteria highlight the critical need for comprehensive and precise cytogenomic data for diagnosis, prognostication, and treatment.
Rashmi Kanagal‐Shamanna, Anna Puiggros, Isabel Granada, Gordana Raca, Katrina Rack, Mar Mallo, Barbara Dewaele, Adam C. Smith, Yassmine Akkari, Brynn Levy, Robert P. Hasserjian, Adela Cisneros, Marta Salido, Guillermo Garcia‐Manero, Hui Yang, M. Anwar Iqbal, Ravindra Kolhe, Francesc Solé, Blanca Espinet   +18 more
wiley   +1 more source

Convergence Of Proliferative And Survival Signals On The pRB/E2F Pathway In Haematopoietic Cells [PDF]

, 2002
Chronic myeloid leukemia (CML) is a malignant stem cell disease characterised by an expansion of myeloid progenitor cells. These cells express a BCR/ABL fusion protein with constitutively activated tyrosine kinase activity, which causes a deregulation of
Parad-Rajmankina, Yelena
core   +1 more source

Unveiling the Burden of Leukemia in Eritrea (2010–2020): Chronic Leukemia Stability, Rising ALL Incidence, and the Enigma of CML in a Low‐Resource Setting

Cancer Reports, Volume 8, Issue 6, June 2025.
ABSTRACT Background and Aims Little research has been conducted on the epidemiology of leukemia in Eritrea. In this retrospective study, we evaluated the burden and trends of acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), and overall leukemia in Eritrea ...
Daniel Mebrahtu Abraha, Samuel Tekle Mengistu, Efriem Ghirmay, Eden Gebresilassie, Ghirmay Embaye Zerat, Rahwa Kokob, Asmeret Tesfazghi, Solomon Negash, Tsega Daniel, Salih Mohammed, Oliver Okoth Achila   +10 more
wiley   +1 more source

BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. [PDF]

, 2006
In chronic myeloid leukaemia, CD34(+) stem/progenitor cells appear resistant to imatinib mesylate (IM) in vitro and in vivo. To investigate the underlying mechanism(s) of IM resistance, it is essential to quantify Bcr-Abl kinase status at the stem cell ...
Copland, M, Elrick, L, Hamilton, A, Holyoake, T, Jørgensen, H, Melo, J V, Mysina, Svetlana   +6 more
core  

Impaired DNA replication within progenitor cell pools promotes leukemogenesis. [PDF]

, 2005
Impaired cell cycle progression can be paradoxically associated with increased rates of malignancies. Using retroviral transduction of bone marrow progenitors followed by transplantation into mice, we demonstrate that inhibition of hematopoietic ...
Ames, Anderson, Andriy Marusyk, Begg, Blagosklonny, Calabretta, Castor, Chang, Choi, Christensen, Christopher C Porter, Christopher Kemp, DeGregori, Dimova, Field, Furgerson, Ganna Bilousova, Gottlieb, Greaves, Hanahan, Hariharan, Jacks, James DeGregori, Jamieson, Just, Kinder, Li, Li, Lightfoot, Lin, Luch, Lundin, Matioli, Milner, Murga, Passegue, Pear, Penit, Pui, Robert D Cardiff, Ryan, Saintigny, Sawyers, Schaefer, Shechter, Sirard, Skibola, Skorski, Spangrude, Sterkers, Van Etten, Wallace-Brodeur, Wong, Wu, Yamasaki, Zhang, Zhu, Zimmerman   +57 more
core   +3 more sources

Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study

Scientific Reports, 2014
BCR-ABL tyrosine kinase plays a major role in the pathogenesis of chronic myeloid leukemia (CML) and is a proven target for drug development. Currently available drugs in the market are effective against CML; however, side-effects and drug-resistant ...
H. N. Banavath, O. P. Sharma, Muthuvel Suresh Kumar, R. Baskaran   +3 more
semanticscholar   +1 more source